表紙
市場調査レポート

MediPoint:冠動脈ステント - EU市場の分析・予測

MediPoint: Coronary Stents - EU Analysis and Market Forecasts

発行 GlobalData 商品コード 320351
出版日 ページ情報 英文 376 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
MediPoint:冠動脈ステント - EU市場の分析・予測 MediPoint: Coronary Stents - EU Analysis and Market Forecasts
出版日: 2014年11月28日 ページ情報: 英文 376 Pages
概要

2011年から2020年にかけてのEU地域の冠動脈ステント市場は、CAGR0.5%のマイナス成長となると予測されています。米国と同様に、市場においては薬剤溶出ステントが最大のシェアを占め、ベアメタルの4倍の規模を持っています。今後の薬剤溶出ステント市場も、転帰の改善やロープロファイルシステムおよび次世代ステントの開発、複数回の手術の必要性の低下によるコストの低減などから、ゆっくりとした速度で成長する見通しです。

当レポートでは、EU地域の冠動脈ステント市場について調査し、冠動脈ステントの種類と概要、冠動脈ステント留置におけるガイドライン、モダリティ、アンメットニーズ、ステント市場への各種影響因子および市場機会の分析、企業および企業間の取り組み、製品および製品開発の動向、主要企業のプロファイル、国別の動向、市場収益の推移と予測などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 産業概要

  • 疾患の概要
  • 臨床的転帰
    • 治療のガイドライン
    • 治療のモダリティ
  • 処置の動向
    • EU
  • 市場へのアクセス
    • 法規制関連のプロセス
    • 医師による意思決定のプロセス
    • GPO(共同購入組織)の役割
    • 臨床データの欠如
    • 地域レベルの制御
    • コストに関する考察
    • 償還の動向
  • 規制上の課題/リコール
    • 規制上の課題
    • 製品リコール
  • M&A・主な提携
    • MedtronicとCovidien
    • Arterial Remodeling Technologiesとテルモ
    • MicroPort Scientific CorporationとCordis Corporation
    • AlvimedicaとCID
    • ITGI MedicalとVascular Solutions
    • テルモとOnset Medical Corporation
    • Atrium MedicalとGetinge Group
    • C.R.BardとClearStream Technologies
    • Biosensors International and Devax・CardioMind・JW Medical Systems
    • CeloNova BiosciencesとNexeon MedSystems
    • MedtronicとInvatec
    • Micell TechnologiesとMaxcor Lifescience
    • Boston Scientific CorporationとGuidant Corporation
    • Abbott VascularとGuidant Corporation
    • カネカとアステラス製薬
  • 冠動脈疾患の経済的影響
    • EU
  • 冠動脈疾患の治療費

第4章 アンメットニーズ

  • 特異的病変におけるより良い臨床的転帰の必要性
    • 慢性完全閉塞
    • 小血管冠動脈病変
    • 重度の石灰化による通過、拡張不能な病変
    • 分岐病変
    • 伏在静脈グラフト手術
  • バルーン血管形成術による障害除去のメカニズム
  • ステント留置の後の心筋梗塞
  • 恒久的ポリマーの除去
  • ステント内の狭窄再発
  • ステント内ステント
  • 長期の抗血小板薬の併用療法
  • 均質な薬剤分布の不足
  • ステント内皮化の遅れ
  • 陰性血管のリモデリング
  • 特定の患者層に有効な治療法の必要性
  • 冠動脈バイパスグラフト術の合併症への対応

第5章 市場機会の分析

  • ステント設計/プラットフォームの改善
    • ステント被覆技術
    • 生体吸収性ステント技術
    • 抗増殖性薬剤と溶出動態
  • ハイブリットステントシステム
  • 困難な冠動脈疾患への有効な治療法
    • 慢性完全閉塞
    • 小血管疾患
    • 分岐病変
    • びまん性アテローム硬化性疾患
    • 伏在静脈グラフト手術
    • 急性心筋梗塞
  • 困難な患者層への対応
  • 新興市場

第6章 市場促進要因・障壁・代替

  • 市場促進要因
    • 疾患の有病率の上昇
    • 困難な冠動脈疾患に有効な治療法
    • ステント技術の革新
    • 生体吸収性ステントの開発
    • 長期の抗血小板薬併用療法の必要性の排除
    • 潜在的なコストの削減
    • 正確なステント留置のための画像診断療法の使用
    • 新興市場でのステントの導入
    • 米国および日本での生体吸収性ステントの発売
  • 市場の障壁
    • オーバースタンティングに関する懸念
    • 薬剤溶出ステント留置後の合併症
    • 手術中の有害イベントのリスク
    • 生体吸収性ステントの吸収の遅れ
    • 償還の不足
    • 医療費削減および償還
    • ベンチャー資金のアベイラビリティ
    • 医療機器物品税
  • 代替
    • 薬剤溶離するバルーン
    • 液剤送達カテーテル

第7章 競合分析

  • 概要
  • 冠動脈ステントの技術開発における動向
    • ベアメタルステントの開発
    • 薬剤溶出ステントの開発
    • 生体吸収性ステントの開発
    • カバードステントの開発
    • 冠動脈ステント技術:SWOT分析
  • 企業の市場シェア:地域別
    • EU

第8章 パイプライン製品

  • 概要
  • パイプライン製品:開発段階別
  • パイプライン製品のプロファイル
    • 生体吸収性ステント
    • その他のタイプの血管ステント

第9章 臨床試験の分析

  • 概要
  • 注目の臨床試験
    • 最新・新世代の薬剤溶出ステントの評価
    • 生体吸収性ステントの臨床試験
    • 困難な冠動脈症状の患者へのステント留置の評価
    • アジア太平洋地域での患者層のターゲット化

第10章 現在および将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Abbott Vascular
    • Boston Scientific Corporation
    • Medtronic
    • Alvimedica
    • Amaranth Medical
    • amg International
    • Arterial Remodeling Technologies
    • B. Braun
    • Balton
    • Biosensors International
    • Biotronik
    • Blue Medical
    • Cardionovum
    • C.R.Bard
    • Elixir Medical Corporation
    • eucatech AG
    • Hexacath
    • IRAMED
    • JW Medical Systems
    • 京都医療設計
    • Lepu Medical Technology
    • MicroPort Scientific Corporation
    • Minvasys
    • MIV Therapeutics
    • Opto Circuits
    • OrbusNeich Medical
    • Relisys Medical Devices
    • REVA Medical
    • Sahajanand Medical Technologies
    • STENTYS
    • テルモ
    • Translumina
    • Vascular Concepts
    • その他

第11章 市場の見通し

  • 市場区分別
    • 概要
    • 薬剤溶出ステント市場
    • ベアメタルステント市場
    • 新しいステント技術
  • 適応症別
  • 地域別
    • EU5ヶ国

第12章 付録

図表リスト

目次
Product Code: GDME1118CFR

The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

The coronary stents market in the EU has an overall negative CAGR of 0.5% over the forecast period from 2011-2020. Similar to the US, the DES market in the EU has the largest share, where the DES market is four times that of the BMS market. Moving forward, GlobalData believes that the DES market will grow slowly due to the improved outcomes, the development of low-profile systems and the next generation of DES, and cost-savings due to the reduced need for repeat intervention.

In the EU, there is a strong dependency on reimbursement, which can vary between nations. German reimbursement has generally been strong for medical devices, and has been less of a problem. However, the other countries are keen to follow clinical outcomes carefully for adoption and product usage in order to obtain reimbursement.

Scope

  • An overview of Coronary Stents, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized EU Coronary Stents market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Coronary Stents.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Coronary Stents sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the EU Coronary Stents market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the US Coronary Stents market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the EU Coronary Stents market landscape Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Disease Overview
  • 3.2. Clinical Outcomes
    • 3.2.1. Treatment Guidelines
    • 3.2.2. Treatment Modalities
  • 3.3. Procedure Trends
    • 3.3.1. European Union
  • 3.4. Market Access
    • 3.4.1. Regulatory Process
    • 3.4.2. Physician Decision-Making Process
    • 3.4.3. Role of Group Purchasing Organizations
    • 3.4.4. Lack of Clinical Data
    • 3.4.5. Regional-Level Control
    • 3.4.6. Cost Considerations
    • 3.4.7. Reimbursement Trends
  • 3.5. Regulatory Issues/Recalls
    • 3.5.1. Regulatory Issues
    • 3.5.2. Product Recalls
  • 3.6. Mergers and Acquisitions/ Key Partnerships
    • 3.6.1. Medtronic and Covidien
    • 3.6.2. Arterial Remodeling Technologies and Terumo Corporation
    • 3.6.3. MicroPort Scientific Corporation and Cordis Corporation
    • 3.6.4. Alvimedica and CID
    • 3.6.5. ITGI Medical and Vascular Solutions
    • 3.6.6. Terumo Corporation and Onset Medical Corporation
    • 3.6.7. Atrium Medical and Getinge Group
    • 3.6.8. C.R. Bard and ClearStream Technologies
    • 3.6.9. Biosensors International and Devax, CardioMind, and JW Medical Systems
    • 3.6.10. CeloNova Biosciences and Nexeon MedSystems
    • 3.6.11. Medtronic and Invatec
    • 3.6.12. Micell Technologies and Maxcor Lifescience
    • 3.6.13. Boston Scientific Corporation and Guidant Corporation
    • 3.6.14. Abbott Vascular and Guidant Corporation
    • 3.6.15. Kaneka Corporation and Fujisawa Pharmaceuticals
  • 3.7. Economic Impact of Coronary Artery Disease
    • 3.7.1. European Union
  • 3.8. Treatment Costs for Coronary Artery Disease

4. Unmet Needs

  • 4.1. Need for Better Clinical Outcomes in Specific Lesions
    • 4.1.1. Chronic Total Occlusions
    • 4.1.2. Small-Vessel Coronary Lesions
    • 4.1.3. Heavily-Calcified and Uncrossable/Undilatable Lesions
    • 4.1.4. Bifurcation Lesions
    • 4.1.5. Saphenous Vein Graft Intervention
  • 4.2. Eliminating Mechanisms of Failure With Balloon Angioplasty
  • 4.3. Late Myocardial Infarction After Stenting
  • 4.4. Eliminating the Permanent Polymer
  • 4.5. In-Stent Restenosis
  • 4.6. Stent-In-Stent Procedures
  • 4.7. Prolonged Dual Antiplatelet Therapy
  • 4.8. Lack of Homogenous Drug Distribution
  • 4.9. Delayed Stent Endothelialization
  • 4.10. Negative Vessel Remodeling
  • 4.11. Need for Effective Therapy for Specific Patient Populations
  • 4.12. Addressing the Complications of Coronary Artery Bypass Grafting

5. Market Opportunity Analysis

  • 5.1. Improve Stent Design/Platform
    • 5.1.1. Stent Coating Technology
    • 5.1.2. Bioabsorbable Stent Technology
    • 5.1.3. Antiproliferative Drug and Elution Kinetics
  • 5.2. Hybrid Stent Systems
  • 5.3. Effective Therapies for Challenging Coronary Indications
    • 5.3.1. Chronic Total Occlusions
    • 5.3.2. Small-Vessel Disease
    • 5.3.3. Bifurcation Lesions
    • 5.3.4. Diffuse Atherosclerotic Disease
    • 5.3.5. Saphenous Vein Graft Intervention
    • 5.3.6. Acute Myocardial Infarction
  • 5.4. Target Challenging Patient Populations
  • 5.5. Emerging Markets

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Market Drivers
    • 6.1.1. Rising Prevalence of Disease
    • 6.1.2. Viable Treatment for Challenging Coronary Indications
    • 6.1.3. Innovations in Stent Technology
    • 6.1.4. Development of Bioabsorbable Stents
    • 6.1.5. Reduce the Need for Prolonged Dual Antiplatelet Therapy
    • 6.1.6. Potential Cost Savings
    • 6.1.7. Use of Imaging Modalities for Accurate Stent Placement
    • 6.1.8. Adoption of Stents in the Emerging Markets
    • 6.1.9. Launch of Bioabsorbable Stents in US and Japan
  • 6.2. Market Barriers
    • 6.2.1. Concerns Regarding Overstenting
    • 6.2.2. Post-ProceduraI Complications of Drug-Eluting Stenting
    • 6.2.3. Risk of Perioperative Adverse Cardiac Events Post-Stenting
    • 6.2.4. Slow Adoption of Bioabsorbable Stents
    • 6.2.5. Lack of Reimbursement
    • 6.2.6. Healthcare Cost-Cutting and Reimbursement
    • 6.2.7. Availability of Venture Capital
    • 6.2.8. Medical Device Excise Tax
  • 6.3. Market Substitutes
    • 6.3.1. Drug-Eluting Balloons
    • 6.3.2. Liquid Drug Delivery Catheter

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Trends in Coronary Stent Technology Development
    • 7.2.1. Development of Bare Metal Stents
    • 7.2.2. Development of Drug-Eluting Stents
    • 7.2.3. Development of Bioabsorbable Stents
    • 7.2.4. Development of Covered Stents
    • 7.2.5. Coronary Stent Technology SWOT Analysis
  • 7.3. Regional Company Market Share
    • 7.3.1. EU Market Share

8. Pipeline Products

  • 8.1. Overview
  • 8.2. Pipeline by Stage of Development
  • 8.3. Pipeline Product Profiles
    • 8.3.1. Bioabsorbable Stents
    • 8.3.2. Other Types of Vascular Stents

9. Clinical Trial Analysis

  • 9.1. Overview
  • 9.2. Clinical Trials to Watch
    • 9.2.1. Evaluating the Latest and New Generation of Drug-Eluting Stents
    • 9.2.2. Bioabsorbable Stent Clinical Trials
    • 9.2.3. Evaluating Stenting in Challenging Coronary Indications/Patient Populations
    • 9.2.4. Targeting Patient Populations in the APAC Region

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Abbott Vascular
    • 10.3.2. Boston Scientific Corporation
    • 10.3.3. Medtronic
    • 10.3.4. Alvimedica
    • 10.3.5. Amaranth Medical
    • 10.3.6. amg International
    • 10.3.7. Arterial Remodeling Technologies
    • 10.3.8. B. Braun
    • 10.3.9. Balton
    • 10.3.10. Biosensors International
    • 10.3.11. Biotronik
    • 10.3.12. Blue Medical
    • 10.3.13. Cardionovum
    • 10.3.14. C.R. Bard
    • 10.3.15. Elixir Medical Corporation
    • 10.3.16. eucatech AG
    • 10.3.17. Hexacath
    • 10.3.18. IRAMED
    • 10.3.19. JW Medical Systems
    • 10.3.20. Kyoto Medical Planning
    • 10.3.21. Lepu Medical Technology
    • 10.3.22. MicroPort Scientific Corporation
    • 10.3.23. Minvasys
    • 10.3.24. MIV Therapeutics
    • 10.3.25. Opto Circuits
    • 10.3.26. OrbusNeich Medical
    • 10.3.27. Relisys Medical Devices
    • 10.3.28. REVA Medical
    • 10.3.29. Sahajanand Medical Technologies
    • 10.3.30. STENTYS
    • 10.3.31. Terumo Corporation
    • 10.3.32. Translumina
    • 10.3.33. Vascular Concepts
    • 10.3.34. Other Companies

11. Market Outlook

  • 11.1. By Market Segment
    • 11.1.1. Overview
    • 11.1.2. Drug-Eluting Stent Market
    • 11.1.3. Bare Metal Stent Market
    • 11.1.4. Emerging Stent Technologies
  • 11.2. By Indication
  • 11.3. By Geography
    • 11.3.1. 5EU

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Report Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
    • 12.4.1. Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI
    • 12.4.2. Bernado Cortese, MD, FESC
    • 12.4.3. Ricardo A. Costa, MD
    • 12.4.4. Thomas Cuisset, MD, PhD, FESC
    • 12.4.5. Nobuyuki Komiyama, MD, PhD, FACC, FJCC
    • 12.4.6. Roger J. Laham, MD
    • 12.4.7. Mark W. Mewissen, MD
    • 12.4.8. Gary S. Mintz, MD
    • 12.4.9. Tudor C. Poerner, MD
    • 12.4.10. David Ramsdale, MD, PhD
    • 12.4.11. Gregory A. Sgueglia, MD, PhD
    • 12.4.12. Madhukar Shahi, MD
    • 12.4.13. Takehiro Yamashita, MD, PhD, FACC
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research Interviews- Physician and Industry Participants
    • 12.5.3. Physican Survey
    • 12.5.4. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD*
  • Table 2: Types of CABG
  • Table 3: Complications of CABG
  • Table 4: Drugs Incorporated Into DES
  • Table 5: Types of Lesions Treated Using Atherectomy
  • Table 6: GPOs in the US and EU
  • Table 7: Direct and Indirect Healthcare Costs of CAD
  • Table 8: Healthcare Expenditures ($bn) for CAD in the 5EU, 2006
  • Table 9: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Table 10: Coronary Stent Technology SWOT Analysis, 2014
  • Table 11: Global Coronary Stent Pipeline Products, 2014
  • Table 12: ART18Z SWOT Analysis, 2014
  • Table 13: DREAMS SWOT Analysis, 2014
  • Table 14: Fantom SWOT Analysis, 2014
  • Table 15: Fortitude SWOT Analysis, 2014
  • Table 16: Ideal BioStent SWOT Analysis, 2014
  • Table 17: Igaki-Tamai Stent SWOT Analysis, 2014
  • Table 18: ON-AVS SWOT Analysis, 2014
  • Table 19: Other Companies Developing BAS, 2014
  • Table 20: FOCUS np Eluting Stent SWOT Analysis, 2014
  • Table 21: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014
  • Table 22: Svelte Drug-Eluting Stent SWOT Analysis, 2014
  • Table 23: Clinical Trials Evaluating the Latest and New Generation of DES, 2014
  • Table 24: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014
  • Table 25: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014
  • Table 26: Abbott Vascular Company Profile
  • Table 27: Abbott Vascular Coronary Stent Marketed Products
  • Table 28: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 29: Abbott Vascular SWOT Analysis, 2014
  • Table 30: Boston Scientific Corporation Company Profile
  • Table 31: Boston Scientific Coronary Stent Marketed Products
  • Table 32: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 33: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 34: Medtronic Company Profile
  • Table 35: Medtronic Coronary Stent Marketed Products
  • Table 36: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 37: Medtronic SWOT Analysis, 2014
  • Table 38: Alvimedica Company Profile
  • Table 39: Alvimedica Coronary Stent Marketed Products
  • Table 40: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 41: Alvimedica SWOT Analysis, 2014
  • Table 42: Amaranth Medical Company Profile
  • Table 43: Amaranth Medical Coronary Stent Pipeline Product
  • Table 44: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 45: Amaranth Medical SWOT Analysis, 2014
  • Table 46: amg International Company Profile
  • Table 47: amg International Coronary Stent Marketed Products
  • Table 48: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 49: amg International SWOT Analysis, 2014
  • Table 50: Arterial Remodeling Technologies Company Profile
  • Table 51: Arterial Remodeling Technologies Coronary Stent Pipeline Product
  • Table 52: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 53: Arterial Remodeling Technologies SWOT Analysis, 2014
  • Table 54: B. Braun Company Profile
  • Table 55: B. Braun Coronary Stent Marketed Products
  • Table 56: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 57: B. Braun SWOT Analysis, 2014
  • Table 58: Balton Company Profile
  • Table 59: Balton Coronary Stent Marketed Products
  • Table 60: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 61: Balton SWOT Analysis, 2014
  • Table 62: Biosensors International Company Profile
  • Table 63: Biosensors International Coronary Stent Marketed Products
  • Table 64: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 65: Biosensors International SWOT Analysis, 2014
  • Table 66: Biotronik Company Profile
  • Table 67: Biotronik Coronary Stent Marketed and Pipeline Products
  • Table 68: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 69: Biotronik SWOT Analysis, 2014
  • Table 70: Blue Medical Company Profile
  • Table 71: Blue Medical Coronary Stent Marketed Products
  • Table 72: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 73: Blue Medical SWOT Analysis, 2014
  • Table 74: Cardionovum Company Profile
  • Table 75: Cardionovum Coronary Stent Marketed and Pipeline Products
  • Table 76: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 77: Cardionovum SWOT Analysis, 2014
  • Table 78: C.R. Bard Company Profile
  • Table 79: ClearStream Technologies Coronary Stent Marketed Products
  • Table 80: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 81: C.R. Bard SWOT Analysis, 2014
  • Table 82: Elixir Medical Corporation Company Profile
  • Table 83: Elixir Medical Corporation Coronary Stent Marketed Products
  • Table 84: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 85: Elixir Medical Corporation SWOT Analysis, 2014
  • Table 86: eucatech Profile
  • Table 87: eucatech Coronary Stent Marketed Products
  • Table 88: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 89: eucatech SWOT Analysis, 2014
  • Table 90: Hexacath Company Profile
  • Table 91: Hexacath Coronary Stent Marketed Products
  • Table 92: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 93: Hexacath SWOT Analysis, 2014
  • Table 94: IRAMED Company Profile
  • Table 95: IRAMED Coronary Stent Marketed Products
  • Table 96: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 97: IRAMED SWOT Analysis, 2014
  • Table 98: JW Medical Systems Company Profile
  • Table 99: JW Medical Systems Coronary Stent Marketed Product
  • Table 100: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 101: JW Medical Systems SWOT Analysis, 2014
  • Table 102: Kyoto Medical Planning Company Profile
  • Table 103: Kyoto Medical Planning Coronary Stent Pipeline Product
  • Table 104: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 105: Kyoto Medical Planning SWOT Analysis, 2014
  • Table 106: Lepu Medical Technology Company Profile
  • Table 107: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products
  • Table 108: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 109: Lepu Medical Technology SWOT Analysis, 2014
  • Table 110: MicroPort Scientific Corporation Company Profile
  • Table 111: MicroPort Scientific Corporation Coronary Stent Marketed Products
  • Table 112: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 113: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 114: Minvasys Company Profile
  • Table 115: Minvasys Coronary Stent Marketed and Pipeline Products
  • Table 116: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 117: Minvasys SWOT Analysis, 2014
  • Table 118: MIV Therapeutics Company Profile
  • Table 119: MIV Therapeutics Coronary Stent Marketed Products
  • Table 120: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 121: MIV Therapeutics SWOT Analysis, 2014
  • Table 122: Opto Circuits Company Profile
  • Table 123: Opto Circuits Coronary Stent Marketed Products
  • Table 124: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 125: Opto Circuits SWOT Analysis, 2014
  • Table 126: OrbusNeich Medical Company Profile
  • Table 127: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products
  • Table 128: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 129: OrbusNeich Medical SWOT Analysis, 2014
  • Table 130: Relisys Medical Devices Company Profile
  • Table 131: Relisys Medical Devices Coronary Stent Marketed Products
  • Table 132: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 133: Relisys Medical Devices SWOT Analysis, 2014
  • Table 134: REVA Medical Company Profile
  • Table 135: REVA Medical Coronary Stent Pipeline Product
  • Table 136: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 137: REVA Medical SWOT Analysis, 2014
  • Table 138: Sahajanand Medical Technologies Company Profile
  • Table 139: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products
  • Table 140: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 141: Sahajanand Medical Technologies SWOT Analysis, 2014
  • Table 142: STENTYS Company Profile
  • Table 143: STENTYS Coronary Stent Marketed and Pipeline Products
  • Table 144: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 145: STENTYS SWOT Analysis, 2014
  • Table 146: Terumo Corporation Company Profile
  • Table 147: Terumo Corporation Coronary Stent Marketed and Pipeline Products
  • Table 148: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 149: Terumo Corporation SWOT Analysis, 2014
  • Table 150: Translumina Company Profile
  • Table 151: Translumina Coronary Stent Marketed Products
  • Table 152: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 153: Translumina SWOT Analysis, 2014
  • Table 154: Vascular Concepts Company Profile
  • Table 155: Vascular Concepts Coronary Stent Marketed Products
  • Table 156: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 157: Vascular Concepts SWOT Analysis, 2014
  • Table 158: Other Companies in the Coronary Stent Market, North America, 2014
  • Table 159: Other Companies in the Coronary Stent Market, EU, 2014
  • Table 160: Other Companies in the Coronary Stent Market, APAC, 2014
  • Table 161: Other Companies in the Coronary Stent Market, South Africa and South America, 2014
  • Table 162: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 163: Global DES Sales ($m) Forecast, 2011-2020
  • Table 164: Global BMS Sales ($m) Forecast, 2011-2020
  • Table 165: EU Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 166: Coronary Stents Market Sales ($m) Forecast for France, 2011-2020
  • Table 167: Coronary Stents Market Sales ($m) Forecast for Germany, 2011-2020
  • Table 168: Coronary Stents Market Sales ($m) Forecast for Italy, 2011-2020
  • Table 169: Coronary Stents Market Sales ($m) Forecast for Spain, 2011-2020
  • Table 170: Coronary Stents Market Sales ($m) Forecast for the UK, 2011-2020
  • Table 171: Primary Research Interviews Completed
  • Table 172: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Pathophysiology of CAD
  • Figure 2: CAD Treatment Modalities
  • Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58)
  • Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58)
  • Figure 5: Types of Stents Used to Treat CAD
  • Figure 6: Example of a BMS
  • Figure 7: Example of a DEB
  • Figure 8: Types of Atherectomy
  • Figure 9: 5EU Coronary Stenting Procedure Volume, 2011-2020
  • Figure 10: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Figure 11: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58)
  • Figure 12: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58)
  • Figure 13: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101)
  • Figure 14: Global Coronary Stents Market Value Share (%), 2013 and 2020
  • Figure 15: EU Market Share for BMS (%), 2013
  • Figure 16: EU Market Share for DES (%), 2013
  • Figure 17: Global Coronary Stent Pipeline Products by Stage of Development, 2014
  • Figure 18: Global Coronary Stents Market Revenue ($m), 2011-2020
  • Figure 19: Global DES Market Revenue ($m), 2011-2020
  • Figure 20: Global BMS Market Revenue ($m), 2011-2020
  • Figure 21: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101)
  • Figure 22: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101)
  • Figure 23: EU Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 24: French Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 25: German Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 26: Italian Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 27: Spanish Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 28: UK Sales ($m) Forecast for Coronary Stents, 2011-2020
Back to Top